• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is BioCryst Pharmaceuticals (BCRX) Undervalued After Its Recent Share Price Slide?

    Simply Wall St·09/12/2026 09:20:05
    語音播報

    BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent share weakness, with the price closing at US$8.12. The move comes alongside mixed return figures over the past year and over a multi year period.

    For BioCryst Pharmaceuticals, the recent 7 day share price decline of 18.47% and 30 day fall of 23.32% sit against a positive year to date share price return of 8.27% and a 3 year total shareholder return of 18.54%. This suggests that momentum has cooled after a stronger multi year run.

    Spot emerging patterns around BioCryst Pharmaceuticals by comparing its recent swings with hand picked 16 high quality undiscovered gems that share strong fundamentals but get far less attention.

    BioCryst Pharmaceuticals has a rare disease portfolio that many investors admire, yet the recent pullback raises a sharper question. Is this a strong business temporarily marked down, or is the stock simply reflecting its true worth today?

    Most Popular Narrative: 61.9% Undervalued

    On the most followed view of BioCryst Pharmaceuticals, a fair value of $21.30 sits well above the recent $8.12 close, which puts a spotlight on the assumptions driving that gap.

    Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins.

    Read the complete narrative. Read the complete narrative.

    Want to see what underpins that valuation spread for BioCryst Pharmaceuticals? The narrative leans on revenue compounding, a sharp margin swing, and a much richer future earnings multiple.

    Result: Fair Value of $21.30 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    Still, the BioCryst Pharmaceuticals story can break if ORLADEYO underperforms expectations or if rising HAE competition and ongoing R&D spend weigh harder on profitability.

    Find out about the key risks to this BioCryst Pharmaceuticals narrative.

    Next Steps

    Mixed messages around BioCryst Pharmaceuticals can be confusing, so review the underlying data carefully. Weigh both the concerns and the positives, and then ground your own view using the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond BioCryst Pharmaceuticals?

    Do not stop your research with BioCryst Pharmaceuticals alone. Use the Simply Wall Street screener to quickly spot other opportunities that could better match your goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.